Disease area
Hematologic malignancies
Multiple myeloma
B-cell malignancies
Myeloid malignancies
Classical hematology
Showing 7 recruiting clinical trials
Advanced or metastatic NSCLC with EGFR gene mutations
COCOON
Phase
NCT06120140
Compound
Amivantamab (EGFR × MET bispecific Ab) + lazertinib (3rd generation EGFR TKI) + dermatologic management ± SOC
Advanced or metastatic NSCLC with EGFR gene mutations
PALOMA-2
Phase
NCT05498428
Compound
Amivantamab (EGFR × MET bispecific Ab) ± lazertinib (3rd generation EGFR TKI) or carboplatin + pemetrexed
Metastatic NSCLC
KaRAnaSa
Phase
NCT07227025
Compound
Amivantamab (EGFR × MET bispecific Ab) + olomorasib
Advanced or metastatic NSCLC with EGFR gene mutations
COPERNICUS
Phase
b
NCT06667076
Compound
Amivantamab (EGFR × MET bispecific Ab) ± lazertinib (3rd generation EGFR TKI) or CT
Locally advanced and unresectable Stage 3 NSCLC
CONVERGE
Phase
NCT06667908
Compound
JNJ-90301900 (NBTXR3) + cCRT + durvalumab
Advanced NSCLC
86974680NSC1001
Phase
NCT06116786
Compound
JNJ-86974680 (A2a receptor antagonist) + cetrelimab (anti–PD-1 mAb) ± RT
Advanced or metastatic solid tumors/metastatic NSCLC
87704916LUC1001
Phase
NCT06311578
Compound
JNJ-87704916 (oncolytic virus) ± cetrelimab (anti–PD-1 mAb)
The safety and efficacy of the investigational use of these products have not been determined.
There is no guarantee that the investigational uses listed will be filed with and/or approved for marketing by any regulatory agency.
Ab, antibody; cCRT, concurrent chemoradiation therapy; EGFR, epidermal growth factor receptor; mAb, monoclonal antibody; CT, chemotherapy; MET, mesenchymal epithelial transition factor; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein-1; RT, radiation therapy; SOC, standard of care; TKI, tyrosine kinase inhibitor.